BD (BDX) Q3 2026 Earnings Call Transcript
BD reported Q3 fiscal 2026 results for “New BD” after its Life Sciences spin-off. Revenue was $4.98B, up 4.4% FX-neutral; adjusted diluted EPS was $3.23, up 4.9%. Adjusted operating margin was 24.9% after 110 bps tariff impact. Full-year adjusted EPS guidance raised to $12.62-$12.72 midpoint; revenue growth guided toward high end of low-single-digit FX-neutral range.
How this was made
The 30-second read
Why it matters
Investors get a full set of earnings datapoints plus a raised FY2026 adjusted EPS range, alongside a quantified FY2027 revenue headwind and margin pressure drivers (tariffs and Alaris remediation end).
Market read
A guidance raise plus quantified margin and next-year headwind provides a clear setup for re-rating BD’s earnings trajectory, with buyback support but growth durability questions into FY2027.
What to watch
Tariff headwind (110 bps) and segment-specific pressures (China dynamics, lower vaccine demand) could drive multiple compression if pricing and productivity offsets prove insufficient.
Background
BD is operating as the “New BD” after the Life Sciences spin-off, with performance driven by structural improvements across growth platforms.
Ticker impact
BD reported Q3 FY2026 revenue of $4.98B, adjusted EPS $3.23, and raised full-year adjusted EPS guidance to $12.62-$12.72 midpoint.
Likely supports upside revisions and buyback sentiment, while the explicit FY2027 headwind may cap the magnitude of any rally.
The article contains multiple primary, decision-relevant datapoints: Q3 results, raised FY EPS guidance, tariff impact disclosure (110 bps), and a quantified FY2027 revenue pressure (200 bps) tied to Alaris remediation.
Market effects
Signals continued demand strength in Medical Essentials, Connected Care, and Interventional, with GLP-1 program agreement momentum supporting med-tech and delivery-adjacent narratives.
Highlights China revenue exposure at 4% and ongoing China market dynamics as a segment pressure point.
Tariff impacts are quantified (110 bps) and may influence how investors model margin resilience for global med-tech supply chains.
Counterpoint
The guidance raise may be more than offset by the disclosed FY2027 200 bps headwind from Alaris remediation ending, suggesting the market could refocus on the next-year growth trough.
Key entities
- companyBD
Reported Q3 FY2026 results and raised full-year adjusted EPS guidance; discussed tariff impacts and FY2027 headwind tied to Alaris remediation.
- executiveTom Polen
CEO who framed the quarter as evidence of growth and earnings potential from the more focused portfolio.
- executiveVitor Roque
CFO who quantified tariff impacts (110 bps) and warned of FY2027 pressure (200 bps) in Q4 due to Alaris comparisons.
